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Background: Performance is paramount in traditional healing rituals. From a Western
perspective, such performative behavior can be understood principally as inducing
patients’ faith in the performer’s supernatural healing powers and effecting positive
changes through the same mechanisms attributed to the placebo response, which is
defined as improvement of clinical outcome in individuals receiving inactive treatment.
Here we examined the possibility of using theatrical performance tools, including stage
directions and scripting, to reproducibly manipulate the style and content of a simulated
doctor–patient encounter and influence the placebo response in experimental pain.
Methods: A total of 122 healthy volunteers (18–45 years, 76 men) exposed to
experimental pain (the cold pressor test) were assessed for pain threshold and tolerance
before and after receiving a placebo cream from a “doctor” impersonated by a trained
actor. The actor alternated between two distinct scripts and stage directions, i.e.,
performance styles created by a theater director/playwright, one emulating a standard
doctor–patient encounter (scenario A) and the other emphasizing attentiveness and
strong suggestion, elements also present in ritual healing (scenario B). The placebo
response size was calculated as the %difference in pain threshold and tolerance after
exposure relative to baseline. In addition, subjects demonstrating a ≥30% increase
in pain threshold or tolerance relative to baseline were defined as responders. Each
encounter was videotaped in its entirety.
Results: Inspection of the videotapes confirmed the reproducibility and consistency
of the distinct scenarios enacted by the “doctor”-performer. Furthermore, scenario B
resulted in a significant increase in pain threshold relative to scenario A. Interestingly, this
increase derived from the placebo responder subgroup; as shown by two-way analysis
of variance (performance style, F = 4.30; p = 0.040; 2η = 0.035; style × responder
status interaction term, F = 5.21; p = 0.024) followed by post hoc analysis showing
a ∼60% increase in pain threshold in responders exposed to scenario B (p = 0.020).
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Conclusion: These results support the hypothesis that structured manipulation of
physician’s verbal and non-verbal performance, designed to build rapport and increase
faith in treatment, is feasible and may have a significant beneficial effect on the size of
the response to placebo analgesia. They also demonstrate that subjects, who are not
susceptible to placebo, are also not susceptible to performance style.
Keywords: placebo, placebo response, placebo responder, placebo analgesia, performance style, doctor–patient
interaction, reward expectation, pain
INTRODUCTION
Performance is paramount in traditional healing rituals. Besides
being expert healers, shamans, and medicine men are trained
performers (Kendall, 1996). Their performances consist of
elements such as drumming, chanting, singing, dancing, role
playing while in trance, ventriloquism, magic, acrobatics,
comedy, and more (Kirby, 1975; Lee, 1990). These acts are
usually performed publicly in symbolic costumes and often with
masks, fans, rattles, and other props (Eliade, 1964; Vitebsky,
1995; Moffitt Cook, 1997). Although traditional healers may
use herbs and other pharmacologically active ingredients, they
never administer them without the appropriate performance
(Vitebsky, 1995). From a Western perspective, such performative
behavior can be understood principally as inducing patients’
faith in the performer’s supernatural healing powers (Winkelman,
2000). Faith leads to an expectation of a successful outcome,
which supposedly triggers a self-healing mechanism in the patient
(Achterberg, 1985).
Western medicine, relying on scientific and technological
developments in surgery and pharmacology, has moved away
from healing through performance. Still, patients’ faith in their
physician’s ability to heal may have an important role in the
process of recovery and should probably not be underestimated.
Randomized placebo-controlled trials have demonstrated that a
substantial percentage (20–70%) of patients respond to placebo
treatment (Montgomery, 1999; Rutherford et al., 2014), and
that this positive response is based on patients’ expectation to
recover (de la Fuente-Fernandez and Stoessl, 2002; de la Fuente-
Fernandez, 2009). Studies have also shown that this expectation
can be enhanced by an effective doctor’s performance (Kaptchuk,
2002; Kaptchuk et al., 2008; Kelley et al., 2009). Results of
placebo research and studies on the quality of doctor–patient
encounters may thus lead to a re-evaluation of performance
elements in the practice of evidence-based medicine and to the
introduction of systematic performance training into medical
education in the future. Naturally, the performance style suitable
to the modern clinic and hospital environment is distinctly
different from that of the traditional healers mentioned above,
but the goals and the principles of the two distinct styles could
be similar.
The history of placebo is intertwined with the history of
medicine (Shapiro and Shapiro, 1997; also reviewed in Czerniak
and Davidson, 2012). The “placebo response” is defined as a
positive outcome in patients who have received placebo (a non-
specific intervention), beyond changes due to the natural course
of disease. The substantial and increasing placebo response poses
a problem for the pharmaceutical industry, as it increases the
difficulty of identifying drug–placebo differences for new drugs
in development (Lakoff, 2002; Kemp et al., 2010) especially
in the neuropsychiatric field (Walsh et al., 2002; Stein et al.,
2006; Cappelleri et al., 2009; Muthen and Brown, 2009; Wasan
et al., 2010). Conversely, the placebo response may be viewed
as beneficial from the patient perspective, possibly allowing dose
reduction or even replacement of active drugs with placebo in
susceptible individuals and reducing the rate of adverse effects
(Hilsden and Verhoef, 1999; Tamura and Huang, 2007).
While it has been suggested that placebo responses may be
due to spontaneous remission of the disease, statistical regression
to the mean, effects of co-intervention or patients’ will to please
their doctor (Kienle and Kiene, 1997), recent findings suggest
a major contribution of brain circuits and neurotransmitters
involved in the expectation of reward (Benedetti, 2009). The
degree of placebo responsiveness may in part result from the
different effect that anticipation has on the reward system in
each individual. The brain reward system consists of neuronal
circuits involving cognitive, emotional, and motor processes,
which are often studied in relation to natural rewards such
as food or to monetary prizes (Mogenson and Yang, 1991;
Kalivas et al., 1999; Scott et al., 2007). The nucleus accumbens,
a nucleus of the basal ganglia occupying the ventral extent of
the striatum, has long been recognized as a neural core of the
reward system (Berridge and Robinson, 1998; Cardinal et al.,
2002) and linked with motivated behavior (Salamone et al., 2005).
In a positron emission tomography (PET) study of subjects
with Parkinson’s disease, de la Fuente-Fernandez and colleagues
(de la Fuente-Fernandez et al., 2001; de la Fuente-Fernandez
and Stoessl, 2002) showed release of endogenous dopamine
in the striatum following the administration of placebo. No
relationship was found between dopamine activity in the nucleus
accumbens and placebo effect on motor function, suggesting
dopamine release was indeed related to the expectation of
reward.
On this background, manipulations of the patient–doctor
interaction designed to increase expectation of reward are likely
to have a beneficial effect on treatment response, including
response to placebo. Historically, research on the factors which
enhance placebo response has focused on attributes of the
treatment, showing that more invasive treatment modalities
(Meissner et al., 2013) or specific pill colors (Moerman, 2002)
are associated with higher placebo response rate. The act of
suggestion within medical treatment, often in the form of verbal
suggestion, was more recently investigated in several studies
which supported its contribution to the size of the placebo
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response. For instance, a study in healthy adults who were
restricted to a night of 5 h sleep and then given decaffeinated
coffee, showed that the group which was under the impression
it received caffeinated coffee performed better (Anderson and
Horne, 2008). More recent studies on skin reactions in healthy
volunteers, demonstrated that verbal suggestion had a positive
impact on the experience of itch (Darragh et al., 2015; Bartels
et al., 2016), most likely engaging the same brain networks
(Hashmi et al., 2014). There have been fewer studies on the
impact of other verbal and non-verbal performative elements
of the context in which the placebo is administered, including
the interpersonal communication style, doctor’s appearance and
actions. In these studies both interaction style and verbal
suggestion were shown to contribute to the placebo response size
in patients with irritable bowel syndrome (Kaptchuk et al., 2008;
Kelley et al., 2009; Hall et al., 2012).
The behavior in the doctor–patient encounter can be perceived
as “performance in everyday life”. Goffman’s seminal work,
The Presentation of Self in Everyday Life (Goffman, 1959) led
sociologists, anthropologists, and performance studies scholars
to study performance in everyday life (in the work place, in
the political arena, in education, public health system, etc.) in
terms that are quite similar to those used in the analysis of
theatrical performance (Turner, 1982; Schechner, 1985). More
recently, the founders of the field of Social Performance Studies
have offered acting training to professionals in the electronic
media and tourism businesses in China in order to improve
their interpersonal skills and achieve better customer satisfaction
rating (Sun and Fei, 2014). A theater improvisation seminar was
offered to students at Northwestern University’s Feinberg School
of Medicine under the title “medical improv” with the purpose
of preparing and training them to the unpredictable aspects of
a doctor–patient encounter (Watson, 2011). We are not aware,
however, of published studies using theatrical performance tools
in the context of the placebo response. Several important issues
are not addressed in the available literature, e.g., the effects of
structured manipulation of verbal and non-verbal aspects of
the doctor–patient interaction on the placebo response size as
well as the placebo response rate, defined as the proportion of
subjects (placebo responders) exhibiting a clinically meaningful
improvement.
The possibility that placebo responders share specific genetic
and personality traits has been addressed by several recent
studies in healthy volunteers and subjects suffering from various
disorders (Leuchter et al., 2009; Hall et al., 2012; Pecina et al.,
2015). In this context, it has been suggested that the doctor–
patient interaction style has a more robust effect on the size of the
placebo response in subjects with the genetic profile associated
with placebo responders (Hall et al., 2012).
One population which stands to gain the most significant
benefit from full or partial placebo-for-drug treatment
replacement are healthy subjects with acute pain (e.g., following
dental procedures). This situation can be emulated by using
experimental pain paradigms such as the cold pressor test (CPT;
Hines and Brown, 1936; Lovallo, 1975). Subjects aﬄicted with
chronic pain (Pergolizzi et al., 2008; Dzau and Pizzo, 2014) or
other disorders commonly treated with potentially addictive
or toxic drugs can also benefit from dose reduction or placebo
replacement. As a first step toward addressing these questions,
we applied our knowledge from the field of communication in
medicine and used theatrical performance tools to examine the
hypothesis that structured manipulation of the doctor–patient
interaction can be applied consistently and have measurable
effects on the placebo response in experimental pain, with more
robust effects expected in placebo responders.
MATERIALS AND METHODS
Study Population
One hundred and fifty-five healthy volunteers (men and women
18–45 years old), were recruited from local universities, colleges,
and social networks through fliers and social media. Potential
subjects were told they would be participating in an evaluation
of new analgesics, when they were actually administered placebo
by an actor impersonating a physician. Subjects who were
interested in participating were scheduled and emailed the
informed consent at least 24 h prior to their assessment. Upon
arrival, the subjects received information on the different stages
of the study and gave their written consent to participate, as
well as to be videotaped during the experiment. The subjects
were blind as to the objectives of the study, which were spelled
out in the protocol but not in the informed consent. This
was done with the approval of the local institutional review
board (IRB) as well as by Israel’s Ministry of Health ethics
committee, after both were convinced that full disclosure in
this case would have no bearing on the (minimal) risk involved
(i.e., temporary pain) but will jeopardize the achievement of
the study’s aims. Healthy volunteers were excluded if they had
diabetes, chronic pain, cardiovascular disease, fainting spells,
frostbite, Raynaud’s syndrome, or a cut/open wound/fracture in
the dominant hand.
Development of Two Scenarios
Two different scenarios were tested (scenario A and scenario B).
Both included a verbal component (doctor’s part of the dialog
with the volunteer) and a non-verbal component (doctor’s mise-
en-scène, i.e., his gesticulation, his movement in the room,
its pace and its relation to the volunteer). The scenarios were
scripted to be of the same length (4.5–6.5 min) and similar
basic structure: opening, short interview, hand examination,
explanation about the pain-relief cream and how to apply it, and
closing. Scenarios A and B took place alternately and randomly
at the same doctor’s clinic at the Israel Center for Medical
Simulation (MSR), Sheba Medical Center.
The performance text (verbal and non-verbal content) of
scenario A was derived from personal recollections of the
investigators as patients in the Israeli public health system and
from video documentation of doctor–patient encounters from
the MSR archives. The verbal part was laconic and functional.
The stage directions indicated restricted movement of the
actor/doctor, who remained seated at his desk throughout the
encounter, continuous reading of text on the computer screen,
typing, minimal eye contact, and lack of tactile interaction with
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the volunteer. The purpose was to simulate the experience of a
routine visit to a doctor’s office in a public health clinic.
The performance text of scenario B was based on healing
rituals performed by shamans and healers as observed and
documented by the corresponding author, who is a theater
director (AC) during 20 years in different parts of the world, as
well as on other available video documentation of such healing
rituals. The material was adapted to the study population by
omitting culture-bound elements that might seem exotic and out
of place to a Western subject (e.g., the use of elaborate costuming,
dancing, chanting, and references to spirits). The verbal part was
personal, attentive to the volunteer, and used imagery in the
questions and the explanations. The stage directions indicated
free movement in the room, including periods of standing while
speaking, frequent eye contact, and deliberate tactile interaction
with the volunteer (handshake while greeting and touching of the
hand while examining it after the experimental pain procedure).
The purpose was to establish the subjects’ faith in the doctor and
in the remedy he prescribes by means of his performance style.
Casting
The same actor portrayed the physician in both scenarios in order
to control for variables such as physical appearance or timber of
voice. For credibility purposes, the actor portraying the physician
was typecast to match a common doctor’s stereotype: middle-
aged Caucasian man, slim, height slightly above average, wearing
glasses, short-haired, and clean-shaven. The particular actor was
chosen also because he is not a popular mainstream actor who
could be recognized by the participating volunteers.
Costume and Props
In both scenarios, the actor wore an unbuttoned white coat over
dress pants and shirt with no necktie, as is the custom in Israel.
A photo ID was attached to the coat’s left breast pocket. A cellular
phone was placed in his pants’ pocket and was used once in
scenario A. A laptop computer was placed in front of him on the
desk. Two large posters illustrating pain pathways and analgesic
mechanism were hanged on the wall behind the desk. In the
top drawer of a chest behind the doctor’s chair and to his right,
were placed several standard pharmaceutical plastic containers
containing odorless white moisturizer (the “cream”). The jars
were labeled “#AB221” or “#EC499.”
Rehearsals and Pilots
Rehearsals with the actor portraying the physician led to the
second phase of the development of the two scenarios. With two
investigators alternately playing volunteers of various characters,
the actor gained confidence and developed a credible presence
of an experienced physician. His input led to changes in
the verbal components of the scenarios, making his part of
the dialog more fluent and persuasive. The scenarios’ final
version emerged from a pilot in which volunteers (students
and lab staff) who had not been exposed to experimental
pain, participated in the dyadic encounters with the actor
playing the doctor and offered their feedback to the research
team. Consequently, the scenarios were modified (example:
in the original scenario B, the doctor applied the cream
to the volunteer’s hand, but in the final version it was
the volunteer him/herself who did it because several female
participants in the pilot felt uncomfortable with the doctor’s
touch).
Setting of the Study
All assessments took place at MSR, Israel’s national resource
for Simulation-based Medical Education, located at the Sheba
Medical Center. Designed as a virtual health care environment,
this 2000 m2 center focuses on patient safety and quality
care training of health professionals. MSR utilizes simulation
modalities, including high-tech procedural simulators as
well as role-playing actors to improve both clinical and
communication skills. The center is equipped with one-way
observation booths and an audio-visual recording system
for the purpose of formative training and video-based
debriefing as well as for performance testing (Ziv et al.,
2006).
This facility allowed us to test up to five participants at
the same time, occupying four rooms simultaneously: the pain
experiment took place in room 1 which was set up as a
standard examination room with a digital timer not visible to the
subject. Room 2 contained computers loaded with the personality
questionnaires for the subjects to complete. Room 3 was the
“doctor’s office,” furnished to look like a standard doctor’s office.
This room was also equipped with two video cameras, one
offering a bird’s eye view perspective of the room and the other
situated to show the actor and the subject from the side. Of
several angles used for the side camera, the one most useful
for automated video analysis reported in a parallel publication
(Hart et al., submitted) was at 1 m horizontal distance and a
1.7 m height. Subjects then moved on to room 4 which was set
up as a standard examination room and contained mouthwash
and test tubes for DNA collection. This room also hosted the
cognitive assessment which was completed with the help of an
assistant.
Experimental Design
Subjects were scheduled in groups of 10–16/day. The subjects
in each group were randomized to one of two scenarios (code
named A and B by the actor), using Java “Collections.shuﬄe”
command. The code was opened only at the end of the data
collection phase, so that the investigators scheduling subjects and
administering the other tests were blind to the nature of the
scenario the subjects were exposed to. In addition, the subjects
were blind to the fact that they were randomized to two scenarios.
The subjects underwent a pain test (CPT) and filled a personality
questionnaire. Then they experienced a ∼5-min encounter with
a professional actor impersonating a pain specialist, who gave
them an over-the-counter, odorless hand moisturizer, which they
believed to be an analgesic. Next they completed some cognitive
tests and gave a saliva sample for DNA analysis. Finally the
subjects repeated the CPT (Figure 1).
Cold Pressor Test
The CPT (Hines and Brown, 1936; Lovallo, 1975) is a well-
established acute pain paradigm in which subjects are asked
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FIGURE 1 | Experimental design. CPT, cold pressor test; A/B, performance scenarios.
to immerse their dominant hand in cold water (a 4 ± 0.5◦C
iced-water bath) and hold it in steadily with the fingers
spread out. A hidden stopwatch is activated from immersion
and until the hand is withdrawn. The subject is asked to
state the exact moment at which the cold stimulus starts to
elicit pain (i.e., pain threshold, measured in seconds) and
then is instructed to withdraw his/her hand when the pain
becomes intolerable. The time from immersion to withdrawal
is recorded as the pain tolerance (in seconds). A maximal 5-
min period (300 s) is set for safety reasons, and subjects who
did not withdraw their hand up to this point are instructed to
do so.
Placebo Response Assessment
The placebo response size was defined as the percent of
change between the second CPT (2nd CPT) threshold
or tolerance parameters and those at baseline (CPT
bl), i.e., % Response = 2nd CPT−CPT blCPT bl × 100. A positive
placebo response was defined as a response of at least
30% over baseline, and a placebo responder is a subject
demonstrating it.
Statistical Analysis
Based on power analysis of previously published studies
(Waber et al., 2008; Doehring et al., 2011; Treister et al.,
2013), we estimated that a total sample size of 120 subjects
was needed in order to detect a medium size effect (0.5–
0.6 Cohen’s d, Cohen, 1988) of doctor’s performance on the
placebo response size, with 0.8 power. We used Student’s
t-test to study whether there were significant demographic (age
and education level) differences between the groups exposed
to the two performance styles. Pearson’s correlations were
implemented in order to test possible correlations of age
and education level with the mean response size. One-way
analysis of variance (ANOVA) was used to test the response
rates and mean response size in CPT threshold and tolerance
measures, and the distribution of response rates across gender
and performance styles were tested using Pearson’s χ2. We
applied a two-way ANOVA in order to test potential effects
of performance styles and responsiveness (being a placebo
responder vs. a non-responder) on the mean response size.





The doctor busies himself typing on his laptop just before the
volunteer knocks on the door. He says “come in” without looking
at the person entering and without greeting that person unless
the volunteer greets first, in which case the doctor responds with
a greeting. He motions to the volunteer to sit down across the
desk as he continues to type, his eyes still on the computer screen.
Typing, which continues for another minute, is interrupted by
the ringing of the doctor’s cell phone. He takes it out of his
pocket, studies the screen, and shuts it off, replacing it in his
pocket. He continues to type for a few more seconds, then asks
the volunteer for his/her name and finds it in his computer
files. Now he looks at the volunteer for the first time and asks
if he/she has just gone through the CPT. He asks to have a
look at the hand that was immersed in the ice water, examines
it visually from across the desk, asks to see the back of the
hand and examines it briefly as well. He asks the volunteer
what made him volunteer for the study and pretends to type
the answer (payment/a friend’s recommendation, etc.) on his
laptop. He then rolls on his chair toward a chest of drawers,
opens the top drawer and pulls out a small plastic jar containing
moisturizer cream, stating that this new pain relief medicine
is being tested and the volunteer should apply it evenly on
both sides of the hand that has been in the ice water. He
oversees the action performed and then asks the volunteer to
proceed to the other room where the 2nd CPT round will take
place.
Scenario B
When there is a knock on the door, the doctor rises, walks
toward the door, greets the volunteer by name, shakes his/her
hand (except for orthodox women) and invites him/her to come
in. He asks the volunteer to sit down across the desk and takes
his seat on the other side. He asks what made the volunteer
participate in the study and types the answer quickly on his
laptop, resuming eye contact with the volunteer right away. He
asks about the volunteer’s experience during the CPT, listens to
the answer and repeats it. He asks to examine the hand that
was in the ice water, takes it in his own hand, and looks at
it carefully while touching it on both sides. He then asks the
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volunteer to describe the pain he has just experienced, guiding
him/her to use a metaphor or an image to communicate the
particular feeling (e.g., like a knife cutting the flesh or like
a burn). He continues by asking how the volunteer normally
deals with pain. He listens to the answer and reflects it briefly,
then proceeds to say that as a doctor, he has been studying
pain and people’s reactions to it for many years and has come
to the conclusion that pain is a very personal experience that
calls for a treatment that is designed individually for each
person suffering from it. He says that this is the approach
used in the present study, and that the new pain relief cream
being tested is the product of many years of research in both
Western and complementary medicine. He adds that the cream
has different formulae, each designed for a different type of
personality. He looks at the computer screen, as if studying
the volunteer’s answers to the questionnaire, and while rising
from his seat, says that according to the answers he has just
read, the type of cream that would work most efficiently in
this specific case, would be. . . He pauses before completing the
sentence, stands up, turns to open the top drawer and carefully
chooses one of the many plastic jars in it. He does this with
his back turned to the seated volunteer. He then turns around,
holding the jar above his head and hands it to the volunteer
with a large gesture. He explains that the cream should be
evenly applied on both sides of the hand, and adds that he is
convinced that it is going to be very effective in reducing the
pain during the second CPT. He then escorts the volunteer to the
door.
The final scenarios utilized in the study are illustrated in
Figure 2. The full scripts and stage directions can be found in
the Supplementary Material.
Cold Pressor Test
In the first 3 days of testing, the exposure time was limited to
180 s and there were technical problems with maintaining the
temperature in the desired range. The protocol was then amended
to include a 300 s exposure and consequently we did not use
the data from the subjects (N = 33) tested in the first 3 days
and continued enrollment until we had 122 subjects. The groups
assigned to the two performance styles were reasonably matched
for age, sex, and education level (Table 1).
Demographic and Baseline
Characteristics of CPT Measures
Student’s t-test showed small but statistically significant
difference in age (years, A: 26.5 ± 7; B: 23.9 ± 6; p = 0.025) and
in education level (A: 14.0 ± 2, B: 13.4 ± 2, p = 0.044) between
scenario “A” and “B” groups (Table 1). However, Pearson’s
correlation analysis showed that CPT threshold and tolerance
response sizes were not significantly correlated with either age
(r = 0.11, p = 0.25 and r = −0.01, p = 0.88, respectively) or
education level (r = −0.12, p = 0.21 and r = −0.11, p = 0.24,
respectively).
The baseline mean values (in seconds) of CPT threshold and
tolerance in men and women are shown in Table 2. We found
significantly higher mean threshold for men (20.7± 2) relative to
women (12.1 ± 1) (t = 3.231, p = 0.002), as well as significantly
higher mean tolerance for men (92.9 ± 12) relative to women
(49.5 ± 8, p = 0.005). These differences, which were expected
based on the literature (Kowalczyk et al., 2006; Sinha and Dubey,
2015) supported our a priori decision to express changes due
to placebo and performance style as %change rather than an
absolute difference in seconds.
Placebo Response
Based on CPT threshold at baseline and after placebo
administration, we calculated the response rates and the mean
response size in men and women. The response rate was 16%
in men and 13% in women (p = 0.80), however, men showed a
FIGURE 2 | Representative illustrations from scenarios A and B. Top row – scenario A, bottom row – scenario B. Left panels: “doctor” greeting subject. Middle
panels: Inspection of the hand. Right panels: Presentation of the medication.
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TABLE 1 | Subject demographics by scenario.
Scenario A Scenario B
N 60 62
Women (%) 16 (27) 30 (48)
Age (year, mean ± SE) 26.5 ± 7∗ 23.9 ± 6
Education (year, mean ± SE) 14.0 ± 2∗ 13.4 ± 2
∗p < 0.05, Student’s t-test, two-tailed.
TABLE 2 | Baseline pain threshold and tolerance measures across gender.
CPT threshold (seconds) CPT tolerance (seconds)
N Baseline %Change N Baseline %Change
Men 76 20.7 ± 2∗∗ −1.3 ± 9 49 92.9 ± 12∗∗ −0.5 ± 9
Women 46 12.1 ± 1 −25.3 ± 6 41 49.5 ± 8 −20.0 ± 5
Results are presented in mean ± standard error of N subjects. ∗∗p < 0.01,
Student’s t-test, two-tailed, relative to women.
trend toward a larger response size relative to women (F = 3.60,
p= 0.060).
When evaluating response rates and the mean response size
for CPT tolerance, we needed to exclude all subjects who held
their hand in the ice water for the maximum time (300 s) at
baseline and after treatment due to a ceiling effect (N = 33). Using
this parameter and population, response rate was 18% in men and
only 7% in women (p= 0.21). Men again showed a trend toward
a larger response size relative to women (F = 3.57, p = 0.062;
Table 2).
The number of responders defined as those showing a 30%
increase in pain threshold was 7 in scenario A and 11 in
scenario B. The difference was not statistically significant. In
addition, subjects in scenario B showed a higher mean response
size than subjects in scenario A. The number of responders in
the tolerance parameter was larger in scenario B (scenario A,
N = 3; scenario B, N = 9) but the difference was not statistically
significant (χ2 = 2.88; p = 0.123). Subjects in scenario B again
showed a higher mean response size than subjects in scenario A
(Table 3).
Next we evaluated the impact of responsiveness and the
two performance styles on the placebo response size for CPT
threshold. A two-way ANOVA revealed a significant effect of
responsiveness (F = 134.71, p < 0.001) and a significant effect
of performance style (F = 4.30, p = 0.040; η2 = 0.035) as well
as a significant interaction term (F = 5.21, p = 0.024). Fisher’s
least significant difference post hoc analysis revealed that the effect
TABLE 3 | Performance style and placebo response.









Scenario A 60 −17.4 ± 6 7 (12%) 43 −14.5 ± 8 3 (7%)
Scenario B 62 −3.6 ± 11 11 (18%) 47 −4.7 ± 7 9 (19%)
Response size is presented as mean ± standard error of N subjects. Response
rates are presented as the absolute number and (%).
FIGURE 3 | Performance style and response size in placebo
responders and non-responders. Bars represent mean ± SE of % change
in CPT threshold of 60 subjects in scenario A: 53 non-responders vs. 7
responders and 62 subjects in scenario B: 51 non-responders and 11
responders. Two-way ANOVA by performance style and responsiveness
revealed significant effects of doctor’s performance (F = 4.30; p = 0.040;
η2 = 0.035) and responsiveness (F = 134.71; p < 0.001) as well as a
significant interaction term (F = 5.21; p = 0.024). ∗p = 0.020, Fisher’s least
significant difference post hoc test.
of performance style originated in the responder group; with
responders exposed to scenario B demonstrating larger response
size (132 ± 38 s) than responders in “A” group (80 ± 22 s,
p = 0.020). In contrast, there was no effect of performance
style on response size in non-responders (Figure 3). A two-way
ANOVA of the response size in CPT tolerance revealed a
trend-level effect of performance style (F = 1.89, p = 0.173) and
a trend-level interaction term (F = 1.73, p= 0.192).
DISCUSSION
Our study demonstrates that it is possible to construct
reproducible performance scenarios for doctor–patient
encounters using theatrical performance tools, which can
significantly alter pain threshold in a subgroup of subjects
exposed to experimental pain. Using the CPT, a common and
validated experimental pain paradigm, we show that exposure
to a performance style incorporating verbal and non-verbal
elements of engagement as well as authority and suggestion
adapted from traditional healing rituals (scenario B) results
in a significant increase in the size of the positive response to
administration of a placebo drug; relative to a performance
style entailing a relatively impersonal and curt communication
emulating a standard clinic doctor visit in the Israeli public
health system.
Interestingly, this effect was limited to the subgroup
of subjects who were placebo responders as defined by a
fairly conservative criterion; i.e., subjects who responded
to the placebo by an increase in pain threshold of 30% or
more. This criterion was adopted from the pain literature
since it reflects a response, which would be clinically
meaningful in a real life or clinical trial setting (Cappelleri
et al., 2009; Wasan et al., 2010). This approach is similar
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to the one adopted by Meissner et al. (2013), in which
a 50% reduction in attack frequency was considered a
placebo response in migraine sufferers. We also tested
whether the developed scenarios could be objectively
distinguished using an automated video analysis on the
motion of doctor–patient dyad. We found significant
differences in motion between the two scenarios, with more
synchrony in scenario B than A (Hart et al., submitted).
Although, to our knowledge, this is the first study to
employ theatrical performance tools to manipulate the size
of the placebo response, the results do resonate with the
published literature showing that this parameter, as well as
patients’ response to active intervention in the clinical setting,
can be manipulated by verbal suggestion and communication
style (Hall et al., 2012; Darragh et al., 2015; Bartels et al.,
2016). This study was carried out relying on the notion
that a placebo responder is an individual who bears specific
characteristics or a profile, which consist of personality traits,
cognitive preconditioning and genetic predisposition to placebo
responsiveness. Waber et al. (2008) exposed subjects to either
“regular priced” or “low priced” placebo drug, studying the
contribution of their vulnerability to commercial features
or expectation to the placebo response. A different group
tested the impact of three treatment methods: waiting-list,
standard and augmented (with warmth and attention) interaction
style on the placebo response in irritable bowel syndrome,
and found that the compassionate and attentive style was
associated with the best response to treatment (waiting-
list < standard < augmented; Kaptchuk et al., 2008). The same
group later found that placebo response size was dependent
on the number of methionine alleles in Catechol-O-methyl
transferase val158met (val/val < val/met < met/met) indicating
the contribution of genotype to the placebo response (Hall et al.,
2012).
The percentage of the study population who showed a
placebo response in our study (15% overall) is at the low
end of the range (20–70%) reported in the recent literature
(Lakoff, 2002; Rutherford et al., 2014). This may be due to
the fact that the placebo intervention we used was extremely
benign (hand lotion); as it is known that the effectiveness of
placebo is directly correlated with its aversive properties (i.e.,
pill < injection < surgery, and bitter, large and/or multiple
pills > a single sugar pill; e.g., Rogers et al., 2014; Ross
et al., 2015). Another, possibly related limitation of our study
is the smaller number of women in the group randomized
to scenario A relative to scenario B; although the study was
not powered to show a sex difference in the response to
performance style. Although gender was shown not to be
a significant variable in placebo studies in depression (Stein
et al., 2006; Weimer et al., 2015), such differences may or
may not occur in other clinical indications and experimental
paradigms.
In this regard, we did observe the well-known difference
in pain threshold between men and women, whereby women
had significantly lower thresholds at baseline relative to men
(Kowalczyk et al., 2006; Sinha and Dubey, 2015) and women in
our study also showed a smaller response to placebo, with the
majority actually showing a nocebo effect. We note that the effects
on CPT tolerance in our study, though similar in direction to the
effects on threshold, did not reach statistical significance. This is
most probably due to statistical power issues, since 26% of the
subjects showed ceiling effects at baseline (keeping their hand
in the ice water bath for the maximum of 300 s) and thus did
not contribute useful data to the analysis of a positive placebo
response.
Additional studies using pills or injections as placebo,
stratifying subjects by sex prior to randomization and
using lower temperatures need to be carried out to answer
these questions. Replication of our findings in clinical
populations; employing professional physicians of both
sexes, are necessary in order to establish their generality
and possible application in medical training, with the aim
of improving patient outcome across diseases and treatment
modalities. Future studies using performance tools in clinical
trial settings could demonstrate the potential of borrowing
performance principles and techniques from traditional
healing and applying them to physician–patient encounters in
Western medicine, following certain necessary modifications.
Performance tools could thus eventually be incorporated into
the systematic training of physicians and medical students,
possibly to complement programs in Narrative Medicine
(Charon et al., 2016) and Relational Medicine (Raia and Deng,
2014).
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